← FDA DRUG APPROVALS

FDA ANDA · ANDA079051

NISOLDIPINE

Sponsor: MYLAN

APPLICATION
ANDA079051
TYPE
ANDA
ORIGINAL APPROVAL
2008-07-25
LATEST ACTION
2022-08-11
ROUTE
ORAL
DOSAGE FORM
TABLET, EXTENDED RELEASE
MARKETING STATUS
Discontinued

Products

NISOLDIPINEDiscontinued
NISOLDIPINE 40MG · TABLET, EXTENDED RELEASE · ORAL
NISOLDIPINEDiscontinued
NISOLDIPINE 20MG · TABLET, EXTENDED RELEASE · ORAL
NISOLDIPINEDiscontinued
NISOLDIPINE 30MG · TABLET, EXTENDED RELEASE · ORAL

Approval history

2022-08-11Labeling · Supplement 5 · standardAP
2008-07-25OriginalLetterAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →